Welcome to the breaking news section for Aridis Pharmaceuticals.
2026
Aridis Provides Corporate Update March 30, 2026
2025
- Aridis Provides Corporate Update April 30, 2025
2024
- Aridis Provides Corporate Update December 20, 2024
- Aridis Provides Corporate Update June 24, 2024
2023
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024 December 15, 2023
- Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business update November 3,2023
- Aridis Pharmaceuticals Announces $2 Million Offering August 2,2023
- Aridis receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301 July 17,2023
- Aridis AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation July 12,2023
- Aridis Pharmaceuticals’ AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs(LPAD) June 20,2023
- Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update June 8,2023
- Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design May 31,2023
- Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q May 25,2023
- Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K April 26,2023
- Aridis Provides Corporate Update March 31,2023
- Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock March 14,2023
- Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients March 13,2023
- Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP) January 25,2023
- New Approaches to Treating Infections in Cystic Fibrosis Patients – AR 501 Phase 2 Trial Update January 17,2023